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Background: Despite progress in the development of combined antiretroviral therapies (cART), HIV infection
remains a significant challenge for human health. Current problems of cART include multi-drug-resistant virus
variants, long-term toxicity and enormous treatment costs. Therefore, the identification of novel effective drugs is
urgently needed.
Methods: We developed a straightforward screening approach for simultaneously evaluating the sensitivity of
multiple HIV gag-pol mutants to antiviral drugs in one assay. Our technique is based on multi-colour lentiviral
self-inactivating (SIN) LeGO vector technology.
Results: We demonstrated the successful use of this approach for screening compounds against up to four HIV
gag-pol variants (wild-type and three mutants) simultaneously. Importantly, the technique was adapted to Biosafety
Level 1 conditions by utilising ecotropic pseudotypes. This allowed upscaling to a large-scale screening protocol
exploited by pharmaceutical companies in a successful proof-of-concept experiment.
Conclusions: The technology developed here facilitates fast screening for anti-HIV activity of individual agents from
large compound libraries. Although drugs targeting gag-pol variants were used here, our approach permits
screening compounds that target several different, key cellular and viral functions of the HIV life-cycle. The modular
principle of the method also allows the easy exchange of various mutations in HIV sequences. In conclusion, the
methodology presented here provides a valuable new approach for the identification of novel anti-HIV drugs.
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Introduction of combined antiretroviral therapy (cART)
has dramatically altered the fate of HIV infected patients.
In most cases, AIDS has changed from a fatal into a
chronic, but manageable disease. Today, more than 25
drugs representing different classes of antiviral agents are
available for combined therapy [1].* Correspondence: carol.stocking@hpi.uni-hamburg.de
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distribution, and reproduction in any mediumDespite this significant progress, there is still a strong
and urgent need to develop novel anti-HIV agents. The
main reasons for that are the following: (i) HIV has
shown a very high capacity to acquire adaptive muta-
tions. In fact, most HIV-infected individuals carry
viruses that are resistant to at least one of the currently
used drugs [2]. (ii) Since cART does not lead to HIV
elimination, patients have to take drug combinations for
their whole life. Therefore, in addition to short-term tox-
icity of any of the individual drugs and, potentially, their
combination, many patients will face long-term adverse
effects, such as liver and renal toxicity. This is associated
with decreasing patient compliance, which in turntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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mutants [2-4].
Thus, novel drugs should ideally combine lower tox-
icity with better anti-HIV efficacy, particularly against
drug-resistant strains. To identify those drugs, easy and
straightforward screening systems are highly desirable.
Two drug-screening systems are frequently used. The
first relies on direct drug-testing on purified HIV
enzymes. That system, however, does not evaluate crit-
ical parameters, i.e. a drug’s ability to penetrate into
cells, compound stability, or cytopathic drug effects.
Moreover, only wild-type enzymes are usually tested.
The second system utilises primary virus isolates and is
therefore much more informative. However, its use for
compound screening approaches is strongly limited by
the rigid safety regulations necessary for using infectious
HIV. As a consequence, only defined (wild-type) viruses
can be used in most cases.
The use of recombinant HIV vector particles to test
drug sensitivity of individual, patient-specific virus variants
has been previously proposed [5,6]. We have extended this
principle by combining it with our modular, multi-colour
LeGO vector system [7]. Based thereon, we could simul-
taneously assess several HIV gag-pol mutants in single
assays. In addition, by adapting the system to use ecotro-
pic viral particles, the assay could be used in a Biosafety
Level 1 environment [8]. We show here that the modular
recombinant vector system facilitates parallel drug-testing
and compound screening on up to four HIV variants at
a time.
Results and discussion
Simultaneous analysis of various gag-pol mutants in single
assay
Screening of potential novel drugs is time-consuming
and expensive. Consequently, concurrent compound
testing ideally targeting different molecules is highly de-
sirable in order to save time and money. We designed
an experimental setting that allows us to perform com-
pound screening for various HIV wild-type and mutant
genes in parallel (Figure 1A). For proof of principle we
used three well-known gag-pol mutants [9].
The proposed system is based on the use of lentiviral
LeGO vectors encoding fluorescent proteins with easily dis-
tinguishable emission spectres, with each given fluorescent
colour corresponding to a defined virus variant, in our case
different gag-pol variant (mutant or wild-type). LeGO vectors
of different colours are then used to transduce target cells of
choice in the presence of known HIV inhibitors or com-
pounds to be tested. Consequently, sensitivity of a given HIV
(gag-pol) variant to an applied drug will result in the loss of
infectivity for the given construct and thus the absence of
the corresponding colour in the transduced cell population.
Thus, the efficiency of a given antiviral compound can bequantitatively assessed using flow cytometry and/or fluor-
escence microscopy (Figure 1A).
Generation of recombinant lentiviral particles containing
mutant reverse transcriptase molecules
For proof of principle we constructed three mutant gag-
pol genes, in which the coding sequences for reverse
transcriptase (RT) contained amino acid substitutions;
namely two gag-pol genes each with two mutations
(D67N/K70R and T215F/K219Q) and one gag-pol gene
containing all four mutations (D67N/K70R/T215F/K219Q).
All enzymes encoded by those mutated genes were previ-
ously shown to confer resistance against the nucleoside
inhibitor azidothymidine (AZT) [9]. Mutant genes were
cloned in the same expression plasmid as the wild-type
gag-pol gene normally used for production of recombinant
lentiviral particles [10].
Mutant or wild-type gag-pol genes were transfected
into 293 T cells in conjunction with plasmids encoding
vesicular stomatitis virus (VSV) G-protein (replacing the
lentiviral Env protein), the lentiviral rev protein, and the
plasmid containing the LeGO-G2 vector, mediating ex-
pression of enhanced green fluorescent protein (eGFP).
Independent of the gag-pol construct used, we obtained
good vector titres in the range of 5×106 to 5×107 infec-
tious particles per ml as estimated on HEK-293 T cells
by FACS analysis (not shown). Concordantly, reasonable
titres (1×105 to 5×105) were also obtained for all mutant
and wild-type gag-pol proteins after pseudotyping with
ecotropic retroviral Env proteins (as assessed on SC1
embryonic murine fibroblasts). Although these viral
titers are sufficient for the assay presented here, viral
vector particles can easily be concentrated using stand-
ard methods, if other cell types or mutations that impact
on functions are used. These results also underline the
flexibility of the system for testing different mutations
and using different cell systems.
Transduction assays allow antiHIV-compound testing
Using the setting described above, we tested two well-
established anti-HIV drugs, namely the nucleoside inhibitor
azidothymidine (AZT) and the non-nucleoside inhibitor
Nevirapine on two different cell lines (murine fibroblasts
SC-1 and human T cells Jurkat). To do so, we independ-
ently transduced target cells with VSV-pseudotyped
LeGO-G2 vectors generated using one of the four differ-
ent gag-pol genes (three mutants, one wild-type) in the
presence of increasing concentrations of the two drugs. In
both cell lines tested, AZT most strongly inhibited trans-
duction of particles containing the wild-type RT as com-
pared to mutant RT, as expected (Figure 1B). In contrast,
Nevirapine suppressed transduction by all lentiviral parti-
cles harbouring any of the four RT variants (Figure 1C). In
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Figure 1 Experimental outline and proof-of-principle. (A) Based on the use of multi-colour LeGO vectors, drug-sensitivity of several (here:
four) RT variants can be assessed simultaneously. (B + C) For proof of principle, two established antiviral drugs (B: AZT, C: Nevirapine) were tested
in independent assays against four RT variants (wild-type, two double mutants [D67N/K70R = NR, T215F/K219Q = FQ] and one quadruple mutant
[D67N/K70R/T215F/K219Q = NRFQ]) pseudotyped with VSV-G protein in two different cell lines (Left panels: SC1 cells, right panels: Jurkat cells). As
expected, RT mutants, but not wild-type RT were highly resistant towards AZT (B). In contrast, all RT variants showed comparable sensitivity
against Nevirapine (C). Data points represent mean values from three independent measurements. P-values that were significantly different
between all other data groups, or only for those connected by lines, are denoted with *, for values < 0.05 or **, for values < 0.01.
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resistant HIV mutants.
Simultaneous testing of different HIV mutants in single
assays
In the next step, we asked whether we could simultan-
eously test several mutants in single assays. At the same
time, we investigated the potential to use ecotropic Envprotein for pseudotyping. Viral vectors pseudotyped with
the ecotropic Env protein are unable to transduce
human cells and are therefore classified as GMO of Bio-
safety Level 1.
In the first experiment, particles harbouring wild-type
RT transduced the blue fluorescent protein Cerulean, while
particles harbouring the quadruple RT mutant (D67N/
K70R/T215F/K219Q) transduced eGFP. As illustrated in
Prokofjeva et al. AIDS Research and Therapy 2013, 10:1 Page 4 of 7
http://www.aidsrestherapy.com/content/10/1/1Figure 2A (left panel), co-transduction of SC1 cells with
both “wild-type” and “mutated” vectors resulted in a mix-
ture of cells expressing eGFP and/or Cerulean. However, in
the presence of 1 μM AZT only very few blue cells are
visible, while the overall viability and absolute numbers
of green cells was unchanged (Figure 2A, right panel).
This observation was confirmed using FACS analysis
(Figure 2B). As clearly evident, the parallel assay pro-
vides a sensitive and controlled assessment of drugFigure 2 (See legend on next page.)sensitivities for different RT variants, which can be eas-
ily quantified (Figure 2C).
Finally, we co-transduced 293 T cells with four differ-
ent LeGO vector particle types – containing wild-type
RT or one of the three named mutants (two double
mutants, one quadruple mutant), each marked with a
different fluorescent tag (tdTomato, eGFP, Venus, or
Cerulean) and pseudotyped with VSV-G protein. Trans-
duction efficiencies were determined for each colour at
(See figure on previous page.)
Figure 2 The use of multi-colour LeGO vectors facilitates simultaneous analysis of different RT variants in single assays. (A)
Fluorescence microscopy demonstrates that vectors encoding Cerulean (packaged using a wild-type RT gene) or eGFP (packaged using the
quadruple RT mutant [D67N/K70R/T215F/K219Q = NRFQ]) efficiently transduce SC1 cells (left panel), but only the vector packaged with the
mutant RT facilitates efficient transduction in the presence of AZT (right panel). (B) AZT-sensitivity of the two RT variants in a dose-dependent
manner was determined by FACS analysis. (C) Quantification of the FACS data from two independent experiments performed in duplicate. (D)
Relative transduction efficiencies of four different lentiviral pseudotypes with the indicated Pol proteins (wild-type [wt], double mutants [D67N/
K70R = NR, T215F/K219Q = FQ] or quadruple mutant (NRFQ) marked by tdTomato (red), Cerulean (blue), eGFP (green), or Venus (yellow),
respectively. SC1 cells were transduced simultaneously with equivalent viral titres with or without AZT and analyzed 96 h post transduction.
Transduction frequency ranged from 20 to 70 %. Shown are the mean values from two independent experiments. (E) AZT per se does not alter
the detection sensitivity for any of the four fluorescent proteins tested. Human 293T cells were infected with lentiviral pseudotypes packaged
with the quadruple RT mutant and containing a vector encoding the indicated fluorescent protein [eGFP, tdTomato (tdTom), Cerulean (Cer), or
Venus]. AZT was added at the indicated concentration 24 h post transduction and analysed 96 h later. Shown are the mean values of four
independent experiments. (F) The comparability of different fluorescent vectors was confirmed by assaying the sensitivity of Pol wt or the
quadruple RT mutant (Pol NRFQ) to various concentrations of AZT with vectors encoding the indicated markers after transduction of human 293T
cells and analysis 96 h post transduction. Transduction frequency ranged from 20 to 55 %. Shown are the mean values of a minimum of three
experiments for each vector. P-values that were significantly different between all other data groups, or only for those connected by lines, are
denoted with *, for values < 0.05 or **, for values < 0.01.
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simple assay, differential drug sensitivity of four different
Pol proteins could be assessed simultaneously – under-
lining the strength and convenience of the assay
(Figure 2B). Furthermore, as viral transductions are per-
formed on the identical cell population, variations in
such assays that occur due to differences in cell growth
are eliminated. A number of additional control experi-
ments were performed to ascertain that drug addition
(e.g. AZT) per se did not alter the fluorescent signal of
the marker protein (Figure 2E) and that results obtained
using different fluorescent markers were comparable
(Figure 2F). In this latter assay, comparable results be-
tween the four fluorescent proteins were obtained for ei-
ther the highly sensitive Pol wt or the relatively resistant
quadruple mutant Pol when tested with different AZT
concentrations (Figure 2F).Figure 3 Applicability for High-throughput screening (HTS). Drug-sens
K70R/T215F/K219Q) proteins was tested using HTS (A) as compared to con
similar results were obtained with both methods. GFP expressing wild-type
mutant strain (filled diamonds/light blue) are shown. HTS analysis was base
that both vectors were pseudotyped with ecotropic envelope protein com
different between the second data group are denoted with *, for values <Taken together, this data demonstrates that the assay
can be used to simultaneously test and/or screen (poten-
tial) antiviral compounds against multiple RT mutants
using up to four fluorescent proteins. Moreover, the ap-
plicability of ecotropic Env proteins and thus the com-
patibility with Biosafety Level 1 facilities have been
shown.
Evaluation of the compatibility of the assay for large-scale
drug screening
In the final step, we asked whether the method could read-
ily be transferred to large-scale compound-screening sys-
tems. To do so, we evaluated the assay in a 384-well plate
format applying an industrial high-throughput screening
(HTS) read-out system. Test plates were automatically
imaged and analysed using the PE Opera confocal LSM
and the Acapella 2.0 software package. The z’ values of theitivity of wild-type (Pol wt) and mutant gag-pol (Pol NRFQ = D67N/
ventional FACS screening (B). As exemplarily shown for AZT, very
strain (filled squares/dark blue) and mCherry-expressing quadruple
d on 2,400 cells whereas 10,000 cells were analysed by FACS. Note
patible with S1 biosafety environment. P-values that were significantly
0.05 or **, for values < 0.0001.
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lar screens [11].
We then compared the HTS assay set-up with results
obtained from individual compound testing. As illustrated
in Figure 3 for AZT, we found a very good correlation
(99.91% at lowest). The HTS data show a slightly higher
standard deviation due to the lower number of analysed
cells, but the differences in 1 μM AZT susceptibility
between wild-type and mutant RT pseudotypes were
highly significant (p <0.001). Taken the reduction in
cost, material and time consumption into account
high-throughput screening will be a practical and effi-
cient alternative to FACS.
Conclusions
We provide here proof of principle for a novel technique
that facilitates the testing of potential novel anti-HIV
drugs simultaneously against different variants of the
virus, as exemplary shown for gag-pol mutants. Since
any compound with the potential to overcome a given
escape mutation will be detected in our assay, it allows
the identification of novel drugs targeting different key
functions of HIV life cycle. Moreover, even molecules
interfering with cellular factors restricting HIV infection
would be identified in this assay. Thus drugs targeting
all viral and cellular factors involved in virus entry, intra-
cellular trafficking, reverse transcription, nuclear import,
and integration can be screened. Furthermore, the
protocol can be easily modified to test newly identified
HIV mutants.
Adaptation of the technique to Biosafety Level 1
conditions has allowed successful upscaling to a high-
throughput screening protocol under industrial condi-
tions. In addition, inclusion of multiple virus variants
(up to four, in the given study) into one assay will sig-
nificantly reduce costs of large-scale screenings. Together,
these two factors should make the proposed technique at-
tractive for companies in both developed and developing
countries. In conclusion, we suppose that the presented
methods will become very valuable for the identification
of novel anti-HIV drugs.
Methods
All molecular cloning was performed using standard
techniques. A DpnI-mediated site-directed mutagenesis
[12] approach was used to introduce point mutations
conferring AZT resistance into the gag-pol gene [9] in
the packaging vector pMDLg/pPRE [10]. Standard cell
culture methods were used as outlined previously [13].
Pseudotyped lentiviral LeGO vector particles were gen-
erated as described [7]. Standard-scale transduction pro-
cedures of different target cells followed the spinoculation
protocol described earlier [7]. FACS analysis of one to four
simultaneous infections was performed on FACS Ariausing a 405 nm laser for detection of Cerulean (457/50 fil-
ter) and a 488 nm laser for detection of eGFP (510/20 fil-
ter), Venus (550/30 filter), and tdTomato (610/20 filter)
(BD Biosciences). For large-scale screening in 384-well-
plates, 3000 SC1 cells per well were incubated, without
centrifugation and without polybrene, in the presence of
virus for 48 h. Imaging was performed using a PE Opera
confocal LSM after fixation with 3% formaldehyde and
nuclei staining (Hoechst33342; 1.5 μM) at 20 fold magnifi-
cation. Images were analysed on single cell level using Per-
kin Elmer Acapella 2.0. Single-cell data of each well were
averaged and used for further analysis. Two-tailed, un-
paired Student’s t-test was used to evaluate significance of
data groups.
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